Acetaminophen Supply Landscape: What Prescribers Need to Know

Acetaminophen remains one of the most prescribed and recommended analgesic/antipyretic agents in clinical practice. While standard oral OTC formulations remain abundantly available, several Acetaminophen-containing products are experiencing supply disruptions that directly impact clinical decision-making. This guide provides an evidence-based overview of current shortages, their root causes, and practical management strategies for providers.

Current Shortage Status (March 2026)

IV Acetaminophen (Ofirmev and Generic Equivalents)

Intravenous Acetaminophen 10 mg/mL (100 mL bags) has been in intermittent shortage since 2023. Key details:

• Hikma Pharmaceuticals: 100 mL bags on back order with estimated availability repeatedly deferred (most recently to late 2025/early 2026).
• Clinical impact: Affects multimodal postoperative analgesia protocols, particularly in settings where IV Acetaminophen is used as an opioid-sparing adjunct.
• Alternatives: Oral or rectal Acetaminophen administration when feasible; IV Ketorolac (with appropriate renal/GI risk assessment); regional anesthesia techniques for opioid-sparing approaches.

Hydrocodone/Acetaminophen Tablets

This Schedule II combination product has faced persistent supply constraints:

• Major Pharmaceuticals discontinued production in late 2024, removing a significant generic supplier from the market.
• DEA aggregate production quotas continue to limit annual manufacturing capacity across all opioid products.
• Clinical impact: Patients with chronic pain management regimens and post-procedural patients may experience delayed or incomplete fills.

Oxycodone/Acetaminophen Tablets

Similar DEA quota-driven constraints and manufacturer consolidation have created intermittent availability gaps for this combination analgesic.

Pediatric Oral Suspension

While not in formal shortage, Acetaminophen 160 mg/5 mL oral suspension remains susceptible to seasonal demand surges during respiratory illness peaks. Supply has stabilized since the 2022 crisis but warrants monitoring during fall/winter months.

Root Cause Analysis

Understanding the drivers of these shortages helps inform prescribing strategies:

• Manufacturer attrition: Continued consolidation in the generic pharmaceutical market reduces supply resilience. When one manufacturer exits (as Major did for Hydrocodone/Acetaminophen), remaining producers cannot rapidly scale to meet demand.
• DEA quota constraints: Annual aggregate production quotas for Schedule II substances have been reduced significantly since 2016 as part of opioid-crisis mitigation. These quotas apply to the total amount of active opioid ingredient manufactured, regardless of demand signals from healthcare systems.
• Quality and compliance: FDA manufacturing facility inspections and resulting corrective actions can temporarily halt production lines, as seen with several IV Acetaminophen manufacturers.
• Global API sourcing: Concentration of active pharmaceutical ingredient (API) production among a limited number of overseas suppliers creates single-point-of-failure risk.

Clinical Management Strategies

For Postoperative/Inpatient Care (IV Acetaminophen Shortage)

1. Transition to oral Acetaminophen as soon as patients can tolerate oral intake. Bioavailability is comparable; IV administration offers faster onset but no significant efficacy advantage for most patients.
2. Rectal suppositories (325 mg or 650 mg) for patients unable to take oral medications. Absorption is variable but provides a reasonable alternative.
3. Prioritize IV Acetaminophen for patients who truly cannot receive oral or rectal formulations (e.g., NPO status with no rectal access, severe nausea refractory to antiemetics).
4. Incorporate regional anesthesia and non-opioid adjuncts (Ketorolac IV, Gabapentin, Ketamine low-dose infusions) into multimodal protocols.

For Outpatient Opioid Combination Shortages

1. Verify availability before prescribing. Direct patients to MedFinder for Providers to check pharmacy stock in real time.
2. Consider alternative strengths or formulations that may have better availability (e.g., switching from Hydrocodone/Acetaminophen 10/325 to 5/325 if clinically appropriate).
3. Prescribe components separately when feasible — standalone opioid plus OTC Acetaminophen can achieve the same analgesic profile.
4. Explore non-opioid alternatives for appropriate patients: NSAIDs (with GI/renal/cardiovascular risk assessment), Tramadol, Gabapentinoids, or topical analgesics.
5. Communicate with pharmacies proactively. Establishing relationships with pharmacy teams helps identify which products are in stock before the patient arrives.

Patient Communication Recommendations

• Set expectations early. Inform patients that certain Acetaminophen combination products may require pharmacy shopping or therapeutic substitution.
• Provide written alternatives. Give patients a prioritized list of acceptable substitutions so pharmacists can make switches without additional provider contact.
• Direct patients to MedFinder for real-time stock checking before they visit the pharmacy.
• Educate on Acetaminophen safety. Remind patients that total daily Acetaminophen from all sources must not exceed 3,000-4,000 mg — especially important when patients may be combining OTC and prescription products.

Resources for Providers

• MedFinder for Providers: Real-time pharmacy stock availability by medication and location.
• ASHP Drug Shortage Resource Center: Current shortage status, estimated resupply dates, and clinical alternatives.
• FDA Drug Shortage Database: Official shortage reporting and manufacturer communications.

For guidance on helping patients manage costs during shortages, see our companion article: How to help patients save money on Acetaminophen. For patient-facing shortage information to share with your patients, see our patient shortage update.